Lymphotoxin-alpha1 beta2 heterotrimer (LTa1b2) (LTa1b2)

The Lymphotoxin-alpha1 beta2 heterotrimer (LTa1b2) is a membrane-anchored cytokine belonging to the tumor necrosis factor (TNF) superfamily, composed of one alpha chain and two beta chains (Gommerman & Browning, 2003, Nat Rev Immunol). Unlike the soluble LTa3 homotrimer, which binds to TNF receptors, LTa1b2 specifically interacts with the lymphotoxin-beta receptor (LTBR), playing a critical role in the development and maintenance of secondary lymphoid organs and immune homeostasis (Ware, 2005, Annu Rev Immunol). Under physiological conditions, LTa1b2 is expressed primarily on activated T, B, and natural killer cells, where it drives the maturation of follicular dendritic cells and organized lymphoid architecture. In chronic inflammatory states, aberrant LTa1b2 signaling is strongly associated with the formation of tertiary lymphoid structures in tissues affected by autoimmune diseases like rheumatoid arthritis and Sjogren's syndrome (Gommerman et al., 2014, Nat Rev Drug Discov). Therapeutic strategies targeting LTa1b2, such as the decoy receptor baminercept or the monoclonal antibody pateclizumab, aim to neutralize the ligand to disrupt chronic inflammatory cycles and prevent pathological tissue remodeling (Kennedy et al., 2013, Arthritis Rheum). This target is of significant interest for treating refractory autoimmune conditions where TNF-alpha inhibitors may be insufficient.

Other names

Membrane-bound lymphotoxinLymphotoxin alpha1 beta2LTa1b2 heterotrimerSurface lymphotoxinTNF-C/TNF-B heterotrimer

Neutralization of the membrane-bound lymphotoxin heterotrimer to prevent its binding and activation of the lymphotoxin-beta receptor (LTBR), thereby inhibiting non-canonical NF-kappaB signaling and reducing ectopic lymphoid tissue formation.